Tranexamic acid is used to reduce excessive bleeding, such as heavy menstrual bleeding or bleeding after surgery or dental procedures. It works by helping blood clots stay in place longer.[2] Cyklokapron is currently approved and in use across 109 indications[4].[1]
Cyklokapron is one of 1486 small molecule programs targeting Arthropathy. It is currently in Approved.
Indications
Total Trials
Active Trials
Competitors
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Competition
2828 competitors in Breast Cancer
Cyklokapron
Prolia
Cymbalta
MS Contin
Effexor
Zoladex
Apatinib Mesylate
Vit D
Tianeptine
Leronlimab
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Regulatory
Dec 30, 1986
CYKLOKAPRON
NDA NDA019281
Dec 30, 1986
CYKLOKAPRON
NDA NDA019280
Nov 13, 2009
LYSTEDA
NDA NDA022430
Apr 15, 2019
TRANEXAMIC ACID
NDA NDA212020
Sources